Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: May 3, 2011


Theo Melas Kyriazi has resigned from Helicos' board of directors. He is an operating executive with SFW Capital Partners. Previously, he worked for 20 years at Thermo Electron (now Thermo Fisher Scientific), most recently as its chief financial officer. He also served as treasurer, vice president of corporate strategy, and CEO of Thermo Spectra. He holds a BA and an MBA from Harvard University.

Life Technologies has named Ora Hirsch Pescovitz to its board of directors. She will replace Ann Reynolds, who is retiring after serving on the board for six years. Pescovitz is the executive vice president of medical affairs and health system chief executive officer at the University of Michigan. Previously, she was the executive associate dean for research affairs at Indiana University School Medicine, the president and CEO of Riley Hospital for Children in Indianapolis, and interim vice president for research administration at Indiana University.

Tal Raz
has become vice president of molecular biology at GnuBio. Previously, she headed RNA assay development at Helicos BioSciences. She has also worked as a research fellow for Children's Hospital Boston and in George Daley's lab at the Whitehead Institute. She holds an MS in epidemiology from the University of California, Los Angeles, and a PhD in genetics from the Technion Israel Institute of Technology.

Ram Laxman has been hired as the vice president of sales and sales operations in Asia at Pacific Biosciences. He joins PacBio after seven years at Illumina, most recently managing its Asian distributor organization across Australia, Taiwan, Korea, Thailand, Malaysia, Philippines, Indonesia, Vietnam, India, and Pakistan. Previously, he spent six years as an application scientist at Illumina and Research Instruments. Laxman holds a PhD in molecular biology from the National University of Singapore's School of Medicine.

Peter Fromen, formerly senior director of investor relations at Illumina, now has a new role as senior director of applications marketing. He will be transitioning investor relations responsibility over the next quarter to Kevin White, who was recently hired as senior director of investor relations. White has spent the last 10 years in the investment community as a buy-side analyst.

Former Life Technologies executive Brian Pollok has been appointed president of biological resource and standards organization ATCC. Pollok was previously the chief scientific officer and head of global research and development at Life Tech. Additionally, he served as vice president of R&D for Invitrogen's discovery sciences group; senior vice president of research and co-founder of Ansata Therapeutics; vice president of discovery research at Aurora Biosciences; senior research investigator for Pfizer; and assistant professor of microbiology and immunology at Wake Forest University. Pollok received his BA in biology and chemistry from the University of Virginia and his PhD from the University of Alabama, Birmingham.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.